Radioactive seed localization of renal cell carcinoma in a patient with Von Hippel-Lindau disease by Hassing, Christina Marie Schiottz et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Radioactive seed localization of renal cell carcinoma in a patient with Von Hippel-
Lindau disease
Hassing, Christina Marie Schiottz; Tvedskov, Tove Filtenborg; Kroman, Niels; Klausen,
Thomas Levin; Djurhuus, Sissal; Langhans, Linnea
Published in:
Clinical Case Reports
DOI:
10.1002/ccr3.685
Publication date:
2017
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Hassing, C. M. S., Tvedskov, T. F., Kroman, N., Klausen, T. L., Djurhuus, S., & Langhans, L. (2017).
Radioactive seed localization of renal cell carcinoma in a patient with Von Hippel-Lindau disease. Clinical Case
Reports, 5(1), 26-28. https://doi.org/10.1002/ccr3.685
Download date: 03. Feb. 2020
CASE REPORT
Radioactive seed localization of renal cell carcinoma in a
patient with Von Hippel-Lindau disease
Christina Marie Schiøttz Hassing1, Tove Filtenborg Tvedskov1, Niels Kroman1,
Thomas Levin Klausen2, Sissal Djurhuus3 & Linnea Langhans1
1Department of Plastic Surgery, Breast surgery and Burns, Rigshospitalet, University of Copenhagen, Denmark
2Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, Denmark
3Department of Urology, Rigshospitalet, University of Copenhagen, Denmark
Correspondence
Christina Marie Schiøttz Hassing, Department
of Plastic Surgery, Breast surgery and Burns,
Rigshospitalet, University of Copenhagen,
Blegdamsvej 9, DK-2100 Copenhagen Ø,
Denmark.
Tel: +45 3545 0516;
Fax: 004535452102;
E-mail: christina.marie.schioettz.
hassing@regionh.dk
Funding Information
Kræftens Bekæmpelse, (Grant/Award
Number: ‘R100-A6761’).
Received: 12 May 2016; Revised: 29 June
2016; Accepted: 12 August 2016
Clinical Case Reports 2017; 5(1): 26–28
doi: 10.1002/ccr3.685
Key Clinical Message
This report describes the case of a patient, who had successful radioactive seed
localization (RSL) performed to improve the identification and excision of a
renal cell carcinoma. RSL is a new method of preoperative localization, which
can ease the surgical procedure, minimize tissue trauma, and ultimately benefit
the patient.
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Introduction
Radioactive seed localization (RSL) is a new method of
preoperative localization involving a small titanium seed
containing radioactive iodine (I-125). RSL is increasingly
applied for localizing nonpalpable lesions in breast cancer
treatment [1], but we believe that RSL has the potential
to be used in various surgical specialties. Few studies have
described the use of RSL outside breast surgery such as
localization of axillary lymph nodes [2, 3] and parenchy-
mal lung lesions [4]. The comprehensive use of imaging
modalities has led to an increased number of detected
suspicious nonpalpable lesions. Identifying these lesions
during surgery and differentiating them from normal tis-
sue is often difficult, and preoperative localization can
therefore be necessary.
The radioactive iodine seed is preoperatively placed in the
center of the suspicious lesion guided by ultrasound. During
surgery, the nonpalpable lesion is located with a handheld
gamma-probe. The incision is made just above the lesion
according to the auditory signal, and the probe allows for a
constant reorientation during the procedure. Correct
removal of the iodine seed is confirmed by measuring activ-
ity in the specimen and no remaining activity in the resec-
tion bed. In contrast to wire-guided localization (WGL),
where the wire needs to be placed on the day of surgery, the
iodine seed can be placed several days before surgery, which
eases the logistic part of the procedure. Additionally, low
rates of complications have been reported [1].
Von Hippel-Lindau (VHL) disease is a genetic neoplasia
syndrome resulting from a mutation in the VHL gene. The
mutation increases the risk of developing malignant
tumors, benign tumors, and cysts in various organs. Exam-
ples of clinical manifestations are hemangioblastomas in
the central nervous system and retina, renal cysts and carci-
nomas, pheochromocytomas and pancreatic cysts [5].
To our knowledge, this case report describes the first
experience of RSL in a patient with VHL disease. In VHL
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patients resection is performed with the objective to spare
as much renal parenchyma as possible and prevent metas-
tasis of the lesions already present [6].
Case Report
A 34-year-old male was diagnosed with VHL disease in
2008. The patient was found to suffer from polycystic
kidneys, a retinal, and cerebellar hemangioblastoma.
In April 2009, he was diagnosed with clear cell-lined
renal cell carcinoma and two tumors in the left kidney
were surgically removed. Following the partial resection
of his left kidney, the patient had annual magnetic res-
onance imaging (MRI) follow-up. In June 2013, two
suspicious lesions were detected in the right kidney and
their size had increased on the following MRI 9 months
later. The lesions were surgically removed in
April 2014. Postoperatively, the patient’s estimated
glomerular filtration rate (eGFR) decreased from 46 to
36 mL/min.
In November 2014, MRI (Fig. 1) showed progression
of a tumor in the right kidney. It was unclear whether it
was a new tumor or recurrence of the primary tumor.
The tumor was located in the central part of the kidney,
which was infiltrated by multiple cysts and considered
very difficult to localize and remove without guidance.
An ultrasound examination performed January 2015 con-
firmed the complicated structure (Fig. 2). Due to reduced
renal function, it was essential to preserve as much func-
tional kidney tissue as possible. Accordingly, ultrasound-
guided RSL was performed. Patient consent was given
before the procedure.
In our institution, we use iodine seeds with an aver-
age activity of 1–3 MBq. Administration and use of the
seeds was performed as described previously [7]. Dur-
ing surgery, the tumor was located with the gamma-
probe and ultrasound guidance. Tumor resection was
performed, and the surgical specimen was sent for
pathological examination, where the iodine seed was
identified and removed. No complications occurred
postoperatively and two weeks following surgery the
patient’s renal function had stabilized with an eGFR of
41 mL/min.
The pathological examination revealed regular kidney
tissue, cysts, and clear cell tumor tissue. Three tumors
were identified within the specimen with diameters of 11,
13, and 16 mm. The tumor tissue was not seen in the
cutting plane, but it was difficult to estimate the margin
status.
Discussion
This case report is the first to our knowledge that
describes the use of RSL in a VHL patient with renal cell
carcinoma. RSL made tumor resection possible, despite
the numerous cysts surrounding the tumor and resulted
in preservation of as much functional kidney tissue as
possible, which may have postponed the patient’s dialysis
treatment.
Partial nephrectomy was chosen in this case due to the
complicated localization of the tumor on ultrasound and
to preserve as much kidney function as possible. In the
surgical treatment of renal cell carcinoma, minimally
invasive techniques have been developed within the last
Figure 1. A coronal T2-weighted MRI from November 2014
illustrating multiple cysts in the pancreas and in both kidneys. The
arrow marks the tumor in the central part of the right kidney.
Figure 2. A longitudinal section of the right kidney illustrating the
multiple cysts, echogenic adipose tissue, and the surrounding renal
cortex. The arrows mark the central serrated tumor.
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10 years. These include radiofrequency ablation (RFA)
and cryoablation. RFA uses alternating current to cause
cell death, and cryoablation causes intracellular ice forma-
tion thereby causing cell death [8]. The techniques can be
performed either laparoscopically or by percutaneous
image guidance [6]. A study comparing RFA with partial
nephrectomy concluded that RFA has an advantage in the
treatment of patients with an age above 60 years or more
than three comorbidities. Partial nephrectomy is preferred
in patients with centrally localized tumors larger than
5 cm or tumors adjacent to the ureter [9].
The iodine seed used had an activity between 1 and
3 MBq, which leads to an absorbed maximum dose of
100 mGy to the surrounding tissue, believed to be accept-
able for the patient. As the iodine seeds are regarded as
sealed radioactive sources, all seeds must be traceable
throughout the entire procedure, which requires extensive
interdisciplinary collaboration.
The experience regarding the use of RSL in other spe-
cialties than breast surgery is sparse. Two studies localiz-
ing axillary lymph nodes with iodine seeds for axillary
staging in breast cancer patients have been published. It
was demonstrated that RSL is a feasible technique and
has a high identification rate of localizing lymph nodes
[2, 3]. Another study has tested the use of RSL of nonvis-
ible or nonpalpable lung lesions prior to video assisted
thoracic surgery with wedge resection. This study con-
cluded that RSL of parenchymal lung lesions is a feasible
technique with complication rates comparable to standard
wire-guided localization [4]. In January 2016, we initiated
a feasibility study where RSL is tested in patients with
suspect nonpalpable lymph nodes in Plastic, Breast and
Head and Neck Surgery.
We believe RSL can improve the localization of suspi-
cious lesions in various surgical specialties, which due to
increasing use of new imaging modalities are detected
earlier, making identification at surgery difficult. RSL may
become an alternative method of localization in a wide
range of surgical specialties and has the potential to
improve treatment by easing the surgical approach. This
may lead to reduced operating time, minimize trauma to
the surrounding tissue, and ultimately benefit the patient.
In conclusion, this case report presents a successful
placement of an iodine seed improving the identification
and excision of a renal cell carcinoma in a complicated
case. Future prospective studies regarding the use of RSL
within urology are necessary to investigate the potential
of the method.
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